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ABSTRACT
Progress Towards Total Synthesis of Hibarimicin B and Its Congeners.
(December 2003)
Nathan Paul Reising, B.A., Wabash College
Chair of Advisory Committee:  Dr. Gary A. Sulikowski
Hibarimicin B (I) was isolated from a soil sample collected in Hibari, Japan, in 1995,
and was identified to be a potent inhibitor of tyrosine kinase via a multi-protein assay.
Chapter I of this thesis describes the biological activity of the hibarimicins, in addition to
an investigation of the biosynthetic pathway leading to the hibarimicins.  Based on this
biosynthetic study, we have identified hibarimicinone (II) and HMP-Y1 (III) as key
synthetic targets.  Chapter II describes a model study investigating the key Hauser
annulation for the synthesis of hibarimicinone (II).  Synthetic progress towards one of
the key intermediates in the synthesis of HMP-Y1 (III) is also presented.  Chapter III
summarizes the work accomplished to date and provides an overview of the necessary
work needed for the total synthesis of hibarimicinone (II) and HMP-Y1 (III).
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1CHAPTER I
INTRODUCTION
1.1  Isolation and Biological Activity of the Hibarimicins
The hibarimicins consist of a family of at least 10 secondary metabolites that
were isolated from a soil sample collected at Hibari, Toyama Prefecture, Japan on June
2, 1995.  They were found during a screening of microbial products for tyrosine kinase
inhibition, the producing soil microorganism was further identified as Microbispora
rosea subsp hibaria TP-A0121 based on DNA-DNA homological comparison to  species
in this genus.1  The structure of five of the ten isolated secondary metabolites,
hibarimicin A (1.1), B (1.2), C (1.3), D (1.4), G (1.5), were elucidated using 2D NMR
analysis, including the use of COSY, CH-COSY, HMBC, NOESY, and NOE
experiments.2  Following structural assignment, hibarimicin B (1.2) was found to be
identical to angelmicin B, a secondary metabolite previously isolated in 1993 from a
culture broth of a strain of Microbispora sp.3  Hibarimicin A (1.1), B (1.2), C (1.3), D
(1.4), and G (1.5), all possess the same aglycon  structure and differ only in the number
and structure of sugars located at the periphery of the compounds.  The structures of the
hibarimicins are shown in Figure 1.1.  Hibarimicins A (1.1), B (1.2), C (1.3), and D (1.4)
were tested in a single assay that allowed simultaneous detection of inhibition of protein
________________
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2kinase A (PKA), protein kinase C (PKC), protein tyrosine kinase (PTK) and calmodulin-
dependent protein kinase III (CAMKIII).1  The results of this experiment showed that all
four hibarimicins specifically inhibited PTK activity, and showed little effect on PKA or
PKC activity.1  IC50 values for the inhibition of PTK ranged from 10 - 40 µg / mL, with
hibarimicin A (1.1) be the most potent of the hibarimicins at inhibiting PTK activity.  In
addition, all four of the hibarimicins assayed inhibited CAMKIII activity1, which is a
common phenomenon with a number of other tyrosine kinase inhibitors including
herbimycin A and tyrphostins.1
Figure 1.1. Structures of the hibarimicins.
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3In addition to the protein tyrosine kinase assay, hibarimicins A (1.1), B (1.2), C
(1.3), and D (1.4) were also tested in vitro for antimicrobial activity.  All four showed
moderate inhibitory activity against Gram-positive bacteria with MICs of 0.8 - 12.5 µg /
mL.1 Furthermore, all four of the hibarimicins showed potent cytotoxicity against  B16-
F10 (murine melanoma) and HCT-116 (human colon carcinoma) cells as summarized in
Table 1.11.
Table 1.1.  In vitro Cytotoxicity of Hibarimicins.
                       IC50 (µg / mL)
B16-F10 HCT-116
Hibarimicin A 1.2 2.5
Hibarimicin B 0.7 1.9
Hibarimicin C 0.8 2.7
Hibarimicin D 2.0 3.6
Uehara and co-workers further investigated the biological activity of hibarimicin
A (1.1) and B (1.2), hibarimicinone (1.6) and HMP-P1 (1.7), a shunt metabolite
produced from a mutant strain of Microbispora rosea subsp. hibaria, (Figure 1.2), in a
multiple protein kinase assay using the postnuclear fraction of v-src transformed
NIH3T3 cells.4  They found that all four compounds potently inhibited the Src PTK
activity, as shown in Table 1.2.  Hibarimicin B (1.2) was more effective at inhibition
4than hibarimicin A (1.1) and hibarimicinone (1.6) was more effective than HMP-P1
(1.7).4  While hibarimicin B (1.2) and hibarimicinone (1.6) showed similar inhibition to
v-src tyrosine kinase activity, hibarimicinone (1.6) showed a 5.5-fold stronger inhibition
against PKC than hibarimicin B (1.2), Table 1.3.4  These results collectively indicate that
while hibarimicinone (1.6) is a slightly stronger inhibitor of src tyrosine kinase activity
than hibarimicin B (1.2), hibarimicin B (1.2) is a much more selective inhibitor than
hibarimicinone (1.6).4
Figure 1.2. Structure of hibarimicinone (1.6), and HMP-P1 (1.7).
1.2  Biosynthetic Studies of the Hibarimicins
Recently Kajiura and coworkers studied the biosynthetic origin of the hibarimicins
using stable isotope feeding experiments.5  Specifically, 13C labeled sodium acetate was
added to a liquid culture of Microbispora rosea subsp. hibaria TP-A0121.
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5 After isolation of hibarimicin B (1.2), NMR analysis revealed incorporatioin of isotope
enriched carbons as summarized in Figure 1.3.5
Table 1.2.  Effects of Hibarimicins, Hibarimicinone (1.6), and HMP-P1 (1.7) on v-src
tyrosine kinase*.
Compound v-Src tyrosinkinase inhibition
Hibarimicin A 1+
Hibarimicin B 2+
Hibarimicinone 3+
HMP-P1 2+
* + after number represents relatively stronger activity
Table 1.3. Effects of Hibarimicin B (1.2) and Hibarimicinone (1.6) on PKC.
Compound IC50 (µM) for PKC
Hibarimicin B 36
Hibarimicinone 6.5
6Figure 1.3.  Incorporation pattern of 13C-labeled acetate.
Assuming a polyketide biosynthetic pathway, this experiment reveals an irregular
distribution of the labeled acetates.  Despite the fact that C14 and C15 correspond to
carbonyl and methyl group of the labeled acetates, respectively, and are directly bound
to each other, there is no 13C-13C coupling seen between them.  The same results are seen
for C14' and C15'.5  Furthermore, C10 and C10' were incorporated from the methyl
group of a labeled acetate fed to the broth, but there is no carbon-carbon coupling
observed in material enriched with [2-13C] acetate.  Kajiura hypothesized that the C10
and C15 came from the same acetate unit and that C14 initially had been attached to an
additional carbonyl carbon, comprising another acetate unit.5  The half unit was formed
from a decarboxylation at C14 and a skeletal rearrangement, involving cleavage of the
C10-C14 carbon-carbon bond, to give the carbon skeleton seen in the half unit of
hibarimicin B (1.2).  After intense INADEQUATE 2-D NMR analysis they found that
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7C10 and C15, and also C10' and C15', indeed originated from the same labeled acetate
unit.5 From this information they concluded that the aglycon of hibarimicin B (1.2) was
Figure 1.4.  Generalized biosynthetic pathway of hibarimicins.
biosynthetically formed through the polyketide pathway, utilizing a dimerization of the
two half units formed from the decarboxylation and skeletal rearrangement of the
starting undecaketide.  Their proposed biosynthetic pathway is shown in Figure 1.4.5
Kajiura did not propose a mechanism for the skeletal rearrangement leading to
cleavage of the C10-C14 bond to provide the carbon skeleton of the hibarimicins.  One
possible mechanism for this rearrangement is proposed in Figure 1.5.  The first steps of
this rearrangement are aldol condensation reactions in order to construct the EF ring
system, followed by a deprotonation at C10 and attack of the resulting enolate on the C9
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8carbonyl.  Next, fragmentation results in cleavage of the C9-C14 bond, with 1,3
migration of an acetate unit to C15 (formation of the C14-C15 bond).  Another
fragmentation then occurs breaking the C15-C10 bond.  The next step in the mechanism
is a deprotonation at C14 and the resulting enolate attacks the carbonyl at C9, thereby
constructing the G ring.  A second deprotonation at C14 then occurs, and the resulting
enolate adds to the carbonyl at C13 to form the H ring, and decarboxylation completes
the carbon skeleton of the EFGH ring system.
9Figure 1.5. Proposed mechanism for the skeletal rearrangement.
Kajiura further investigated the biosynthetic pathway leading to the hibarimicins
by the isolation and structure elucidation of shunt metabolites.6  The blocked mutants
from this experiment were obtained by exposure of  M. rosea  subsp. hibaria TP-A012
to the mutating agent, N-methyl-N'-nitro-N-nitrosoguanidine (NTG).  Initially nine
hundred sixty colonies were gathered after mutagenesis, none of which produced
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hibarimicins.  Five of these colonies possessed the characteristic red color of the
hibarimicins and were selected for further analysis.6
After further investigation of these mutants by fermentation in various media
they isolated key intermediates on the biosynthetic pathway leading to the hibarimicins,
summarized in Figure 1.6.6 Polyketide (1.8) undergoes a cyclization and skeletal
rearragement affording tetracycle (1.9), the presumed precursor to the key dimerization.
Tetracycle (1.9) then undergoes an oxidative coupling to afford the symmetrical
metabolite HMP-Y1 (1.10).  The symmetrical compound then undergoes an oxidation of
the E and F rings and formation of the furan linkage bridging the GH ring system to
furnish hibarimicinone (1.6). Hibarimicinone (1.6) then undergoes a series of
glycosylations to furnish the hibarimicins, including hibarimicin B (1.2).6 Isolation of
HMP-Y1 (1.10) demonstrates that the dimerization of the two half units occurs first on
the biosynthetic pathway, followed by oxidation of the E and F rings  and furan
formation, and then finally the glycosylation reactions that account for the difference in
the hibarimicins. From this information we identified HMP-Y1 (1.10) and
hibarimicinone (1.6) to be valuable intermediates in the synthesis of hibarimicin B (1.2),
and chose these as our synthetic targets in order to correlate our synthetic products with
known natural products.
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Figure 1.6. Proposed biosynthetic pathway to hibarimicin B (1.2).
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1.3 Synthetic Analysis of Hibarimicinone (1.6) and HMP-Y1 (1.10)
From the work done by Kajiura and co-workers, we identified hibarimicinone (1.6) and
HMP-Y1 (1.10) as synthetic targets in our labs.  We have contemplated multiple
strategies for our synthetic approach to hibarimicinone (1.6) and HMP-Y1 (1.10).    For
hibarimicinone (1.6) we envision using a palladium mediated Suzuki or Stille cross
coupling in the late stages of the synthesis to couple the ABCD and EFGH ring systems.
For HMP-Y1 (1.10) we have more options for our synthetic strategy, due to the
symmetrical nature of the target metabolite.  One of our options is the application of a
palladium mediated coupling reaction to dimerize the tetracycle in the late stages of our
synthesis, similar to our synthetic strategy for hibarimicinone (1.6).  A second approach
is to form the aryl-aryl bond early in the synthesis and utilize a bi-directional approach
for the synthesis of HMP-Y1 (1.10).  This strategy was used by Hauser and co-workers
in their synthesis of Biphyscion (1.13) (Scheme 1.1).7  We are currently investigating all
three of these strategies for the total synthesis of hibarimicinone (1.6) and HMP-Y1
(1.10).
13
Scheme 1.1. Hauser's Synthesis of Biphyscion (1.13).
1.3a Synthetic Analysis of Hibarimicinone (1.6)
Our major disconnections for the total synthesis of hibarimicinone (1.6) are
shown in Scheme 1.2. We envision that hibarimicinone (1.6) can be assembled by a
palladium mediated cross coupling between tetracycles, 1.15 and 1.16.  This
transformation may be accomplished in one of several ways, including a Suzuki or Stille
cross-coupling reaction.  The Suzuki coupling reaction would involve the coupling of the
aryl-boronic acid 1.15 (M = B(OR)2) with the bromo-quinone 1.16 (X = Br). The Stille
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Scheme 1.2. Retrosynthetic Analysis of Hibarimicinone (1.6).
coupling reaction would consist of the coupling of the aryl-stannane 1.15 (M = SnR3)
with the bromo-quinone 1.16 (X = Br).  These two tetracycles may be synthesized from
a Hauser annulation between enone 1.17 and the lactone 1.18, and a Hauser annulation
with cyanophthalide 1.19 and the furan bridged enone 1.20.  Lactone 1.18 and
cyanophthalide 1.19 are therefore points of departure for our synthetic studies.  Lactone
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1.18 was anticipated to be synthesized from a series of directed ortho-metallalations
(DoM) starting from MOM protected 3,4 dimethoxyphenol.  Similarly, the
cyanophthalide 1.19 could be synthesized from a series of DoM reactions starting from
MOM protected p-methoxyphenol.
1.3b  Synthetic Analysis of HMP-Y1 (1.10):  Cross-Coupling Approach
One retrosynthetic analysis for HMP-Y1 (1.10), similar to that of hibarimicinone
(1.6) (Scheme 1.2), is outlined in Scheme 1.3.  The metabolite HMP-Y1 (1.10) may be
constructed using either a palladium mediated dimerization of the aryl-stannane 1.15a or
a oxidative aryl coupling of tetracycyle 1.15b.  The tetracycle 1.15 is proposed to be
formed from the Hauser annulation of the lactone 1.18 and the enone 1.17. The lactone
1.18, which is our synthetic target, may be constructed using a series of DoM reactions.
Tetracycle 1.15 for construction of HMP-Y1 (1.10) is potentially one of the coupling
partners required for construction of hibarimicinone (1.6).
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Scheme 1.3.  Retrosynthetic Analysis of HMP-Y1 (1.10):  Cross-Coupling Approach.
1.3c Synthetic Analysis of HMP-Y1 (1.10):  Bi-directional Approach
Our second synthetic strategy for the synthesis of HMP-Y1 (1.10) involves
constructing the central aryl-aryl bond and assembling the target structure in bi-
directional fashion, as illustrated in Scheme 1.4.  From this retrosynthetic approach we
envision that HMP-Y1 (1.10) may be synthesized from a bis-Hauser annulation of the
bislactone 1.21 and the enone 1.17.  The bislactone 1.21 is our synthetic target and may
be synthesized from a series of directed ortho metalation reactions starting from the
biaryl compound 1.22.  The biaryl compound 1.22 may be constructed using a palladium
mediated dimerization reaction to construct the central aryl-aryl bond.
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Scheme 1.4. Retrosynthetic Analysis of HMP-Y1 (1.10): Bi-Directional Approach.
1.4  Literature Precedent for Aryl-Quinone and Aryl-Aryl Bond Formation
As discussed earlier, there are several methods available for the construction of
the aryl-quinone bond required to complete the core carbon structure of hibarimicinone
(1.6).  The most viable of these options would consist of the Suzuki cross coupling
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between the aryl-boronic acid and the aryl halide.  Fukuyama and co-workers have
shown in their synthesis of mastigophorenes A and B, the ability to couple the highly
substituted aryl-boronic acid  1.23 with bromo-quinone 1.24 in good yield,8 as shown in
Scheme 1.5.  The most widely excepted mechanism for the Suzuki coupling consists of
an oxidative addition-transmetalation-reductive elimination sequence,9 as shown in
Scheme 1.6.  In this reaction, the rate limiting step is the oxidative addition of the
palladium catalyst into the R-X bond.9
Scheme 1.5.  Fukuyama's Aryl-Quinone Suzuki Coupling.
Scheme 1.6.  Mechanism of Suzuki Coupling.
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Another commonly used method for aryl-quinone bond formation is the Stille
coupling which entails the palladium mediated coupling of aryl stannes with halo-
quinones.  This has been recently demonstrated by Stagliano and Malinakova, where
they coupled the hypervalent iodo-quinone 1.26 with the aryl-stannane 1.27, (Scheme
1.7).10  The mechanism of the Stille coupling closely resembles the Suzuki coupling.
The initial step is an oxidative addition of the palladium catalyst into the R-X bond,
followed by a transmetalation of the aryl group with loss of trialkyltin halide.  Reductive
elimination of R-R' then occurs to give the desired product and recycle the Pd(II) to
Pd(0), which may then repeat the cycle.9
Scheme 1.7. Stagliano's Aryl-Quinone Coupling.
Aryl-aryl bond formation has also been used widely in synthetic chemistry, and
is a valuable tool for the formation of a variety of biaryl compounds.  A wide variety of
methods are available for such transformations, including Suzuki coupling, Stille
coupling, and oxidative coupling.9  Suzuki and Stille aryl-aryl couplings are closely
O
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related to the aryl-quinone couplings previously discussed.  These conditions may be
used for the coupling of aryl-halides with aryl-boronic acids and aryl-stannanes,
respectively.  Another viable route to the formation of biaryl bonds is oxidative
coupling.  Bringmann and Tasler have shown that dimerization of phenols may occur
under oxidative conditions, despite bis-ortho substitution at the coupling site.11
Bringmann used di-tert-butyl peroxide (DTBP) as an oxidizing agent for the
dimerization of the phenol 1.29 to provide the biaryl complex 1.30 in 80% yield, as
shown in Scheme 1.8.11 There is a variety of alternative oxidants available for oxidative
coupling such as Cu(II)12 salts, Pb(OAc)4, Ag2O, FeCl3, a variety of hyper-valent iodine
reagents, O2 and others.11  There is also a variety of possible mechanisms for this type of
reaction, and they are widely based on the nature of the substrate.  In general two
electrons and two protons are removed from the substrates during the oxidation, the
location of which is based on the functionality found on the aromatic ring.13
Scheme 1.8.  Bringmann's Oxidative Coupling of Phenols.
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1.5 Literature Precedent for Directed ortho Metalations
Directed ortho metalation (DoM) reactions have been widely used in the synthesis of
highly substituted aromatic rings.  The directing metalation group (DMG), a Lewis base,
coordinates to an alkyl lithium and directs the deprotonation of the aromatic ring to the
ortho position of the DMG.14  Once deprotonation occurs, the reaction may be quenched
with a variety of electrophiles, such as CO2, TMS-Cl, acid chlorides, DMF, and alkyl
halides.15  Strong alkyl lithium bases are the preferred bases for DoM reactions, and are
usually used in combination with a bidentate ligand such as TMEDA.  TMEDA helps
break the aggregates of alkyl lithiums into monomers and dimers, thereby making them
stonger and more reactive bases.14  One example of DoM reactions reported by Snieckus
is shown in Scheme 1.9.15  In this reaction, s-BuLi is added to the benzamide 1.31 at -
78oC and quenched with CO2 to give the benzoic acid 1.32 in 89% yield.
Scheme 1.9.  Example of Directed ortho Metallation Reaction.
In summary, we propose a synthesis of hibarimicinone (1.6) and HMP-Y1 (1.10).
We have chosen to use aryl-quinone, aryl-aryl bond formation, and directed ortho
metallations in order to synthesize the target compounds.  These types of reactions are
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89%
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well precedented in the literature and provide ample methods for the eventual synthesis
of hibarimicinone (1.6) and HMP-Y1 (1.10).
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CHAPTER II
SYNTHETIC PROGRESS TOWARD THE AB AND GH RING
SYSTEM OF HIBARIMICINONE AND HMP-Y1
2.1 Synthetic Progress Toward Hibarimicinone (1.6):  Model Study
As illustrated in the retrosynthetic analysis of hibarimicinone (1.6), Scheme 1.2, a
Hauser annulation between the cyanophthalide 1.19  and the enone 1.20 will be used to
construct the EFGH ring system. A model study was performed in order to test the
viability of the Hauser annulation and the subsequent reactions necessary to complete
the EFGH fragment of hibarimicinone (1.6). The model study initially consisted of the
synthesis of the known cyanophthalide 2.5 from commercially available p-methoxy
phenol 2.1 as outlined in Scheme 2.1.
Scheme 2.1. Synthesis of the known cyanophthalide 2.5.
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Commercially available p-methoxyphenol 2.1 was protected using NaH and
MOM-Cl in 89 - 95% yield.16  The resulting MOM protected phenol 2.2 underwent a
DoM reaction using n-BuLi and TMEDA followed by quenching with diethylcarbamyl
chloride to afford the aryl amide 2.3 in 50 - 80% yield.15  This compound was then
subjected to a second DoM reaction using t-BuLi, TMEDA,  and quenching with DMF
to afford the formylated compound 2.4 in yields ranging from 68 to 77%.15  The
formylated product 2.4 underwent a lactonization using a combination of TMS-CN,
KCN, and 18-crown-6 followed by stirring in AcOH to afford the cyanophthalide 2.5 in
76% yield.17
With the cyanophthalide 2.5 in hand, we investigated the Hauser annulation with
commercially available 2-cyclohexen-1-one 2.6 using LDA as the base which provided
the dihydroquinone (2.7) in 61 - 72% yield,18 (Scheme 2.2).  The dihydroquinone 2.7
was then methylated using Cs2CO3 and MeI to provide the tricycle 2.8 in 44 - 58%
yield.19  Upon treatment of 2.8 with 6 M HCl the free phenol 2.9 was obtained in 97%
yield.20  Surprisingly, in our attempt to perform an ortho-bromination reaction on phenol
2.9 using either NBS21 or Bu4NBr322 we observed no halogen incorporation.  The only
observed product was the quinone 2.10, as determined by NMR analysis, resulting from
oxidation of the free phenol, Scheme 2.3.
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Scheme 2.2. Synthesis of phenol 2.9.
Scheme 2.3. Synthesis of quinone 30.
This model study provided valuable information for the synthesis of the EFGH
ring system of hibarimicinone (1.6).  Specifically, we developed reaction conditions for
the key Hauser annulation for our synthesis.  We also determined that a second route
must be developed in order to incorporate the halide/metal functional group, necessary
for the coupling of the tetracycles 1.14 and 1.15, prior to deprotection of the phenol.
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Finally, the model study showed us that oxidation of the terminal aromatic ring should
be the preferred ring for oxidation over the internal aromatic ring.
2.2 Synthetic Progress Toward HMP-Y1 (1.10): Cross-Coupling Approach
Examination of the retrosynthetic analysis for hibarimicinone (1.6) and HMP-Y1
(1.10), shown in Schemes 1.2 and 1.3, reveals that the ABCD tetracycle is a common
intermediate that may be used in the synthesis of both of these target structures.  This
intermediate will be derived from lactone 2.11 (Figure 2.1).
Figure 2.1. Common intermediate in the synthesis of hibarimicinone (1.6) and
                   HMP-Y1 (1.10).
We have examined the synthesis of intermediates 2.11a and 2.11b.  For 2.11a the
synthesis starts from 3,4 dimethoxy phenol 2.13 which was alkylated to yield MOM
ether 2.14 in 85 -95% yield, (Scheme 2.4).16  The MOM ether 2.14 was treated with NIS
and a catalytic amount of TFA in CH3CN to afford the aryl iodide 2.15 in 93 - 97%
yield.23  The aryl iodide was then subjected to a carbonylation reaction using Pd(PPh3)4
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as a catalyst in THF containing fifteen equivalents of diethylamine under 1 atm of CO to
afford the aryl amide 2.16 in 66% yield.24  We anticipate formylation using DoM
methodology followed by reduction of the formyl group and cyclization are necessary to
synthesize lactone 2.11a.  This work is currently under investigation in our laboratory.
In addition to the synthetic work developed in connection with lactone 2.11a we
have also worked toward intermediate 2.11b, (Scheme 2.5).  The MOM ether 2.14 was
treated with n-BuLi and TMEDA followed by a TMS-Cl quench to furnish the aryl
silane 2.18 in 88 - 92% yield.15  The aryl silane 2.18 underwent another DoM reaction
using n-BuLi and TMEDA, and quenching with iodine to furnish the aryl iodide 2.19 in
51% yield.15  The aryl iodide 2.19 underwent a carbonylation reaction using the
previously described carbonylation conditions to afford the aryl amide 2.20 in 44 - 61%
yield.24  The formylation, reduction of the resulting aldehyde, and cyclization are
currently under investigation in our laboratory.
Scheme 2.4. Synthetic Work Toward lactone 2.11a.
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Scheme 2.5. Synthetic Work Toward lactone 2.11b.
2.3 Synthetic Work Toward HMP-Y1 (1.10):  Bi-Directional Approach
In addition to the work previously discussed, we have investigated an alternate
strategy for the synthesis of HMP-Y1 (1.10).  This strategy involves the formation of the
central aryl-aryl bond then utilizing a bi-directional approach to the synthesis of HMP-
Y1 (1.10), as shown in Scheme 1.4.  Sesamol derivatives were used for a model study to
investigate the coupling chemistry needed to construct the central aryl-aryl bond.  The
synthesis of these sesamol derivatives are summarized in  Scheme 2.6.  Sesamol 2.22
was MOM protected using NaH and MOM-Cl to afford the protected phenol 2.23 in 90 -
98% yield.16  The MOM protected phenol 2.23 was treated with n-BuLi and TMEDA
followed by quenching with I2 to afford the aryl iodide 2.24 in 70 - 86% yield.15
Similarly, when the MOM ether 2.23 was subjected to n-BuLi and TMEDA, quenching
with B(OMe)3 the boronic acid 2.25 was achieved in 62 - 75% yield.15  Utilizing the
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same deprotonation conditions and quenching with Me3SnCl, the aryl stannane 2.26 was
achieved in 72% yield.15
Scheme 2.6. Synthesis of Sesamol Derivatives.
With the aryl iodide 2.24 and the boronic acid 2.25 in hand, we investigated the
Suzuki coupling reaction of these two substrates to afford the coupled biaryl complex
2.27.  A variety of conditions were investigated and summarized in Table 2.1.25,26 The
best yield for the Suzuki coupling reaction of the aryl iodide 2.24 with the boronic acid
2.25 was achieved when Na2CO3 was used as the base at room temperature in a solution
of DMF : H2O (9:1).25  However, optimal conditions required 5.0 equivalents of the
boronic acid 2.25 and afforded the coupled product 2.27 in only 30% yield.  In addition,
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Suzuki coupling reaction also requires the synthesis of two structurally distinct
substrates.  Collectively, this information persuaded us to investigate another synthetic
route to biaryl 2.27.
Table 2.1. Conditions for Suzuki Coupling Reaction.
Base Temp Solvent Eq. BoronicAcid Yield
NaOH (4 eq.) rt DMF:H2O( 9 : 1 ) 2 4 %
TlOEt (1.8 eq.) rt THF:H2O( 3 : 1 ) 2 No Rxn
NaOH (5 eq.) rt DMF:H2O( 9 : 1 ) 5 28 %
NaOH (5 eq.) 50 oC DMF:H2O( 9 : 1 ) 5 8 %
TlOEt (5 eq.) rt DMF:H2O( 9 : 1 ) 5 Trace
Na2CO3 (5 eq.) rt
DMF:H2O
( 9 : 1 ) 5 30 %
In 1999, Corey and co-workers developed a new dimerization method using
Pd(PPh3)4 as a catalyst, CuCl, and CuCl2, in a solution of DMSO.27 When the aryl
stannane 2.26 was subjected to these conditions, the dimerized product 2.27 was
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obtained in 56% yield, (Scheme 2.7).27  However, when the aryl stannane 2.28 was
subjected to these conditions a diminished yield of 38 - 43% of the dimerized product
2.29 was achieved.  One possible explanation for this occurrence is that the free methoxy
groups add more steric hinderance at the coupling site, compared to the less sterically
hindered sesamol derivative.
Scheme 2.7. Corey Conditions for Dimerization Reaction.
Corey did not propose a mechanism for the dimerization of the aryl-stannane.  A
possible mechanism is shown in Scheme 2.8. The first step in the proposed mechanism
is a transmetalation of the aryl group, with loss of R3SnCl, followed by an oxidative
addition of the Pd(0) into the resulting aryl-Cu bond.  A ligand exchange then occurs
replacing the Cu ligand with a chloride, with the reduction of CuCl2 to CuCl.  The
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palladium inserts into a second Ar-Cu bond with loss of CuCl to afford the Ar-Pd-Ar
complex, which then undergoes a reductive elimination to afford the biaryl product and
recycle the Pd(II) to Pd(0), which may then repeat the cycle.
Scheme 2.8. Proposed Mechanism for the Corey Dimerization.
This comprises the work done to date on the previously mentioned target structures in
our synthesis of hibarimicinone (1.6) and HMP-Y1 (1.10).  Further research toward the
completion of these target compounds is currently under investigation in our
laboratories.
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2.4 Experimental Section
Materials and Methods. All reactions were carried out under an argon
atmosphere using dry glassware which had been flame-dried in vacuo unless otherwise
noted.  Diethyl amine, TMEDA, and diisopropyl amine were all distilled from CaH2 and
stored over KOH prior to use.  Reactions were monitored by thin-layer chromotography
using 0.25-mm E. Merck precoated silica gel plates. Visualization was accomplished
with UV light and aqueous potassium permanganate solution or aqueous
phosphomolybdic acid solution as a stain followed by charring on a hot plate.
Purification was accomplished using flash liquid chromotography with the stated
solvents using silica gel 60 (particle size 0.040-0.063 mm).  All yields correspond to
chromatographically and spectroscopically pure compounds unless otherwise noted.
Unless otherwise stated, melting points are uncorrected values.  1H and 13C NMR spectra
were obtained from a Varian-300 or 500 spectrometers at ambient temperature.  1H and
13C NMR are reported using δ values relative to CDCl3 unless otherwise noted.  Infrared
spectra were recorded using a Nicolet Impact 410 spectrometer. Low and High-
resolution mass spectra were obtained from the Texas A&M University Mass
Spectrometry Service Center on a PE Sciex Qstar Electrospray Ionization (ESI) mass
spectrometer.
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Dihydroquinone 2.7. To a solution of diisopropyl amine (0.13 mL, 0.93 mmol)
in THF (3 mL) was added n-BuLi (0.58 mL of a 1.6 M solution in hexanes, 0.93 mmol)
dropwise at -78 oC. The resulting solution was stirred at -78 oC for 0.5 h  and 2.5 (116
mg, 0.467 mmol) in THF (4 mL ) was added dropwise. The reaction mixture was stirred
at -78 oC for 1 h.  2-cyclohexen-1-one 2.6 (45 µL, 0.47 mmol) was  added  dropwise to
the reaction at -78oC and the mixture was stirred at 21 oC for 25 min. Water (5 mL) was
added and the aqueous layer extracted with EtOAc (3 x 5 mL), dried (MgSO4),
concentrated in vacuo and the residue was purified by flash liquid chromatography (2:1
hexane : EtOAc) to afford 88 mg of 2.7  (61 %) as an orange solid: mp 126-130 oC
(DCM);  IR (CH2Cl2) 3452, 1660, 1527 cm-1; 1H NMR (500 MHz, CDCl3) δ 9.45 (s,
1H), 6.98 (d, J = 8.5 Hz, 1H), 6.90 (d, J = 9 Hz, 1H), 5.24 (s, 2H), 4.02 (s, 3H), 3.60 (s,
3H), 2.98 (t, J = 6.5 Hz, 2H), 2.73 (t, J = 6.5 Hz, 2H), 2.09 (m, 2H), -1.71 (s, 1H); 13C
NMR (126 MHz, CDCl3) δ 205.8, 157.2, 151.6, 150.9, 141.6, 121.3, 121.0, 118.1, 113.8,
112.7, 109.9, 97.6, 57.2, 56.7, 39.4, 23.1, 22.2; HRMS (ESI) m/z 325.1222 [(M + Li)+,
calcd for C17H18O6 325.1263].
MOMO
MeO OH
OH O
2.7
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Tricycle 2.8. To a solution of 2.7 (212 mg, 0.688 mmol) in DMF (24 mL ) was
added Cs2CO3 (1.2 g, 3.4 mmol) followed by iodomethane (0.86 mL, 14 mmol). The
resulting mixture was heated at 50 oC for 22 h.  Water (30 mL) was added and the
aqueous layer extracted with EtOAc (3 x 50 mL), washed with water (2 x 30 mL) and
brine (30 mL), dried (MgSO4), concentrated in vacuo and the residue was purified by
flash liquid chromatography (2 :1 hexane : EtOAc) to afford 100 mg of 2.8 (44 %) as an
orange solid:  mp 77-82 oC (DCM); IR (CH2Cl2) 2926, 1652 cm-1; 1H NMR (500 MHz,
CDCl3) δ 7.06 (d, J = 8.5 Hz, 1H), 6.88 (d, J = 8.5 Hz, 2H), 5.15 (s, 2H), 3.95 (s, 3H),
3.89 (s, 3H), 3.75 (s, 3H), 3.58 (s, 3H), 3.09 (t, J = 10 Hz, 2H), 2.68 (t, J = 10 Hz, 2H),
2.07 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 198.3, 154.8, 151.6, 149.1, 149.1, 133.1,
125.4, 124.8, 123.4, 115.7, 109.6, 98.2, 63.5, 61.8, 57.1, 56.7, 41.3, 23.9, 22.5;  HRMS
(ESI) m/z 347.1387 [(M + H)+, calcd for C19H22O6 347.1495].
MOMO
MeO OMe
OMe O
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Phenol 2.9. To a solution of 2.8 (8.8 mg, 0.026 mmol) in THF (0.9 mL ) was
added water (0.36 mL) and 6M HCl (0.92 mL).  The resulting solution was heated at 50
oC for 4.5 h.  The reaction was then poured into brine (3 mL), extracted with EtOAc (3 x
3 mL), dried (MgSO4), concentrated in vacuo, and the residue was purified by flash
liquid chromatography (2 :1 hexane : EtOAc) to afford 7.5 mg of 2.9, (97 %) as an
orange solid:  mp 114-117 oC (DCM); IR (CH2Cl2) 3432, 1650, 1521 cm-1; 1H NMR
(500 MHz, CDCl3) δ 9.88 (s, 1H), 6.98 (d, J = 8.5 Hz, 1H), 6.83 (d, J = 9 Hz, 1H), 4.00
(s, 3H), 3.94 (s, 3H), 3.78 (s, 3H), 3.13 (t, J = 6 Hz, 2H), 2.71 (t, J = 6.5 Hz, 2H), 2.11
(m, 2H); 13C NMR (126 MHz, CDCl3) δ 197.7, 155.2, 150.6, 149.7, 148.4, 132.6, 124.6,
121.4, 118.7, 113.0, 110.8, 64.6, 61.8, 57.8, 41.3, 24.0, 22.4; HRMS (ESI) m/z 303.1246
[(M + H)+, calcd for C17H18O5 303.1232].
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OMe OMe
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Quinone 2.10. To a solution of 2.9 (22.3 mg, 0.075 mmol) in DMF (1.5 mL),was
added NBS (14.6 mg, 0.082 mmol) at 0 oC and the reaction was allowed to warm to 21
oC over 7 h.  Water (3 mL) was added and aqueous layer was extracted with EtOAc (3 x
3 mL), washed with water (2 x 3 mL) and brine (3 mL), dried (MgSO4), concentrated in
vacuo, and the residue was purified by flash liquid chromatography (4 :1 hexane :
EtOAc) to afford 13 mg of 2.10 (62 %) as an orange solid:  mp 163-167 oC (DCM); IR
(CH2Cl2) 2969, 1644, 1604 cm-1; 1H NMR (500 MHz, CDCl3) δ 6.87 (d, J = 10Hz, 1H),
6.85 (d, J = 10.5 Hz, 1H), 3.95 (s, 3H), 3.87 (s, 3H), 3.05 (t, J = 6 Hz, 2H), 2.70 (t, J = 6
Hz, 2H), 2.13 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 196.2, 184.5, 183.6, 157.1, 153.7,
148.8, 139.6, 138.2, 134.1, 128.0, 125.2, 63.7, 62.0, 40.4, 24.3, 22.0; HRMS (ESI) m/z
287.0923 [(M + H)+, calcd for C16H14O5 287.0919].
O
O OMe
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Aryl-Iodide 2.15. To a solution of NIS (101 mg, 0.451 mmol) and TFA (0.010
mL, 12 mmol) in CH3CN (0.64 mL) was added 2.14 (81.2 mg, 0.410 mmol) in CH3CN
(1 mL) at 21 oC.  The reaction stirred at 21 oC for 2 h and was poured into saturated
NaHCO3 (2mL), the aqueous layer was extracted with EtOAc (3 x 5 mL), washed with
saturated Na2S2O3 (3 mL) and brine (3 mL), dried (MgSO4), concentrated in vacuo and
the residue was purified by flash chromatography (4:1 hexane : EtOAc) to afford 0.12 g
of 2.15 (93 %) as a dark pink solid:  mp 67-70 oC (DCM); IR (CH2Cl2) 2949, 1577, 1498
cm-1;1H NMR (500 MHz, CDCl3) δ 7.19 (s, 1H), 6.76 (s, 1H), 5.17 (s, 2H), 3.87 (s, 3H),
3.84 (s, 3H), 3.55 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 151.1, 150.3, 145.5, 121.5,
101.6, 96.4, 74.8, 56.8, 56.7, 56.3;  HRMS (ESI) m/z 331.0020 [(M + Li)+ calcd for
C10H13O4I 331.0019].
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Aryl-Amide 2.16.  A flask containing Pd(PPh3)4 (769 mg, 0.666 mmol) was
purged with CO, and 2.15 (360 mg , 1.11 mmol) in THF (11 mL ) and then HNEt2 (1.7
mL, 17 mmol) were then added at 21 oC.  Carbon monoxide was bubbled into the
reaction mixture for 20 min and the reaction was stirred at 21 oC for 22 h under 1 atm of
CO.  The reaction was diluted with Et2O (30 mL), filtered through a plug of silica gel,
concentrated in vacuo and the residue was purified by flash chromatography (1:2 hexane
: EtOAc) to afford 0.22 g of 2.16 (66 %) as as a light orange solid: mp 81-81 oC
(CH2Cl2); IR (CH2Cl2) 2941, 1664, 1551 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.47 (s
1H), 6.77 (s, 1H), 5.13 (s, 2H), 3.95 (s, 3H), 3.91 (s, 3H), 3.51 (q, J = 7.0 Hz, 2H), 3.51
(s, 3H), 3.26 (q, J = 7.0 Hz, 2H), 1.27 (t, J = 7.9 Hz, 3H), 1.20 (t, J = 7.0 Hz, 3H); 13C
NMR (126 MHz, CDCl3) δ 189.3, 168.7, 156.0, 155.0, 144.9, 111.2, 99.6, 95.7, 56.6,
56.5, 56.4, 41.9, 38.5, 13.7, 13.0; LRMS (ESI) m/z 298 [(M + H)+, calcd for C15H23NO5
298].
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Aryl-Silane 2.18. To a solution of 2.14 (434 mg, 2.19 mmol) and TMEDA (0.36
mL, 2.4 mmol) in THF (5.5 mL) at 0 oC was added n-BuLi (0.91 mL of a 2.6 M solution
of hexanes, 2.4 mmol) dropwise.  The ice bath was removed and the reaction mixture
stirred at 21 oC for 1 h.  The mixture was then cooled to 0 oC and trimethylsilyl chloride
(0.84 mL, 6.6 mmol) was added and the mixture was allowed to warm to 21 oC over 3.5
h.  The reaction was then diluted with water (10 mL) and the aqueous layer extracted
with EtOAc (3 x 10 mL), dried (MgSO4 ),  concentrated in vacuo and the residue was
purified by flash chromatography (20:1 hexane : EtOAc) to afford 0.52 g 2.18 (88 %) as
light yellow oil: IR (CH2Cl2) 2950, 1583, 1465 cm-1; 1H NMR (500 MHz, CDCl3) δ 6.85
(d, J = 8.5 Hz, 1H), 6.79 (d, J = 8.5 Hz, 1H), 5.10 (s, 2H), 3.82 (s, 3H), 3.80 (s,3H), 3.47
(s, 3H), 0.34 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 156.3, 154.6, 147.8, 122.1, 114.7,
108.9, 94.8, 61.1, 56.4, 56.1, 1.6; HRMS (ESI) m/z 277.1442 [(M + Li)+. Calcd for
C13H22O4Si 277.1447].
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Aryl-Iodide 2.19. To a solution of 2.18 (488 mg, 1.80 mmol) and TMEDA (0.30
mL, 2.0 mmol) in THF (9 mL) at 0 oC was added n-BuLi (0.84 mL of a 2.36 M solution
in hexanes, 2.0 mmol) dropwise.  The ice bath was removed and the mixture stirred at
room temperature for 2 h.  Iodine (503 mg, 1.98 mmol) in THF (5.8 mL) was added at 0
oC and the reaction mixture was allowed to warm to 21 oC over 2.5 h.  The reaction was
then poured into saturated Na2S2O3 (10 mL), extracted with EtOAc (3 x 10 mL), washed
with brine (10 mL), dried (MgSO4), concentrated in vacuo and the residue was purified
by flash chromatography (20:1 hexane : EtOAc) to afford 0.36 g 2.19 (50 %) as an
orange oil: IR (CH2Cl2) 2940, 1646 cm-1; 1H NMR  (300 MHz, CDCl3) δ 7.30 (s, 1H),
4.93 (s, 2H), 3.84 (s, 3H), 3.83 (s, 3H), 3.62 (s, 3H), 0.35(s, 9H); 13C NMR (126 MHz
CDCl3) δ 155.1, 153.8, 149.9, 128.2, 124.4, 100.7, 84.8, 61.0, 58.9, 56.3, 1.7; HRMS
(ESI) m/z 403.0423 [(M + Li)+, calcd for C13H21IO4Si 403.0414].
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Aryl-Amide 2.20. A flask containing Pd(PPh3)4 (61 mg, 0.052 mmol) was
purged with CO,  and 2.19 (35 mg, 0.087 mmol) in THF (0.87 mL ) and HNEt2 (0.14
mL, 1.3 mmol) were then added at 21 oC.  Carbon monoxide was bubbled into the
reaction for 20 min and the reaction stirred at 21 oC overnight under 1 atm CO.  The
solution was diluted with Et2O (3 mL), filtered through a silica plug, concentrated in
vacuo and the residue was purified by flash chromatography (3 :1 hexane : EtOAc) to
afford 20 mg of 2.20 (60 %) as a thick orange oil: IR (CH2Cl2) 2940, 1646 cm-1; 1H
NMR (500 MHz, CDCl3) δ 7.34 (s, 1H), 4.94 (s, 2H), 3.94 (s, 3H), 3.86 (s, 3H), 3.51 (q,
J = 7.0 Hz, 2H), 3.34 (s, 3H), 3.25 (q, J =  7.0 Hz, 2H), 1.25 (t, J = 7.0 Hz, 3H), 1.16 (t,
J = 7.0 Hz, 3H), 0.35 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 190.3, 167.4, 160.2, 157.7,
148.8, 123.3, 116.0, 102.3, 61.1, 58.6, 56.1, 42.3, 38.8, 14.0, 12.7, 1.6; HRMS (ESI) m/z
370.2081 [(M + H)+, calcd for C18H31NO5Si 370.2050].
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Aryl-iodide 2.24.  To a solution of 2.23 (507 mg, 2.79 mmol) and TMEDA (0.46
mL, 3.1 mmol) in THF (7 mL) at 0 oC was added n-BuLi (1.3 mL in a 2.4 M solution of
hexanes, 3.1 mmol) dropwise.  The ice bath was removed and the reaction mixture
stirred at 21 oC for 13 min and then cooled to 0 oC.  Iodine (1.42 g, 5.58 mmol) in THF
(7 mL) was added dropwise.  The mixture was allowed to warm to 21 oC over 4.5 h.
The reaction mixture was poured into saturated Na2S2O3 (10 mL) and the aqueous layer
extracted with EtOAc (3 x 10 mL) dried (MgSO4), concentrated in vacuo and the residue
was purified by flash chromatography (10:1 hexane : EtOAc) to afford 0.74 g 2.24 (86
%) as a pink solid:  mp 56-58 oC (CH2Cl2); IR (CH2Cl2) 2900, 1613, 1454 cm-1; 1H
NMR (500 MHz, CDCl3) δ 6.69 (d, J = 8.5 Hz, 1H), 6.56 (d, J = 8.5 Hz, 1H), 6.02 (s,
2H), 5.16 (s, 2H), 3.53 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 151.6, 150.5, 141.8,
108.3, 107.9, 107.7, 101.2, 96.3, 56.7; HRMS (ESI) m/z 314.9714 [(M + Li)+, calcd for
C9H9IO4 314.9706].
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Boronic Acid 2.25.  To a solution of 2.23 (1.10 g, 6.05 mmol) and TMEDA (1.0
mL, 6.7 mmol) in THF (15 mL) at 0 oC was added n-BuLi (2.8 mL in a 2.4 M solution
of hexanes, 6.7 mmol) dropwise.  The ice bath was removed and the reaction mixture
stirred at 21 oC for 13 min and then cooled to 0 oC.  Trimethyl borate (3.4 mL, 30 mmol)
was added and the reaction mixture was allowed to warm to 21 oC over 3 h.  Water (15
mL) was added and the aqueous layer was extracted with EtOAc (3 x 15 mL), dried
(MgSO4), concentrated in vacuo and the residue was purified by flash chromatography
(4:1 to 2:1 hexane : EtOAc) to afford 0.95 g 2.25 (70 %) as a gray solid:  mp 71-74 oC
(CH2Cl2); IR (CH2Cl2) 3432, 1634, 1460 cm-1; 1H NMR (500 MHz, CDCl3) δ 6.84 (d, J
= 14 Hz, 1H), 6.63 (d, J = 14 Hz, 1H), 6.31 (s, 2H), 6.03 (s, 2H), 5.23 (s, 2H), 3.51 (s,
3H); 13C NMR (126 MHz, CDCl3) δ 156.6, 153.3, 142.1, 111.1, 106.5, 101.7, 96.7, 95.0,
56.7;  HRMS (ESI) m/z 249.0563 [(M + Na)+, calcd for C9H11BO6 249.0546].
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Aryl-Stannane 2.26.  To a solution of 2.23 (1.02 g, 5.61 mmol) and TMEDA
(0.93 mL, 6.2 mmol) in THF (14 mL) at 0 oC was added n-BuLi ( 2.8 mL of a 2.2 M
solution in hexanes, 6.2 mmol) dropwise.  The ice bath was removed and the reaction
mixture was stirred at 21 oC for 13 min and then cooled to 0 oC.  Trimethyltin chloride
(11 mL, of a 1 M solution in THF, 11 mmol) was added and the reaction was allowed to
warm to room temperature over 4 h.  Water (15 mL) was added and the aqueous layer
was extracted with EtOAc (3 x 15 mL), dried (MgSO4), concentrated in vacuo and the
residue was purified by flash chromatography (10:1 hexane : EtOAc) to afford 1.4 g 2.26
(72 %) as yellow oil: IR (CH2Cl2) 2904, 1624, 1434 cm-1; 1H NMR (500 MHz, CDCl3) δ
6.68 (d, J = 8 Hz, 1H), 6.50 (d, J = 8 Hz, 1H), 5.87 (s, 2H), 5.08 (s, 2H), 3.46 (s, 3H),
0.35 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 157.2, 154.0, 141.4, 110.5, 108.5, 104.8,
100.4, 95.1, 56.1, -7.7; HRMS (ESI) m/z 353.0403 [(M + Li)+, calcd for C12H18O4Sn
353.0387].
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Example Procedure for Synthesis of Biaryl 2.27 Using Suzuki Conditions.
To a solution of 2.24 (36 mg, 0.12 mmol), 2.25 (132 mg, 0.586 mmol), and Pd(PPh3)4
(14 mg, 0.012 mmol) in DMF:H2O (9:1) (0.5 mL) was added Na2CO3 ( 62 mg, 0.59
mmol) at 21 oC.  The reaction mixture was stirred at room temperature for 2 d.  The
solution was diluted with Et2O (3 mL) and the resulting mixture was filtered through a
plug of silica gel, washed with water (3 x 3 mL) and then brine (3 mL), dried (MgSO4),
concentrated in vacuo and the residue was purified by flash chromatography (4:1 hexane
: EtOAc) to afford 14 mg 2.27 (33 %) of an orange oil: IR (CH2Cl2) 2922, 1639, 1445
cm-1; 1H NMR (500 MHz, CDCl3) δ 6.77 (d, J = 8.5 Hz, 1H), 6.70 (d, J = 8.5 Hz, 1H),
5.95 (d, I = 1.5 Hz, 1H), 5.93 (d, J = 1.5 Hz, 1H), 5.01 (d, J = 1.5 Hz, 2H), 3.36 (s, 3H);
13C NMR (126 MHz, CDCl3) δ 150.8, 146.8, 142.8, 108.6, 107.9, 107.0, 101.6, 96.6,
56.1; HRMS (ESI) 369.1161 [(M + Li)+, calcd for C18H18O8 369.1162].
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Biaryl 2.27.  A flask containing Pd(PPh3)4 ( 36 mg, 0.031 mmol), CuCl (156 mg,
1.58 mmol), and CuCl2 (85 mg, 0.63 mmol) was purged with argon (3x) and 2.26 (109
mg, 0.315 mmol) in DMSO (3.2 mL) was added dropwise at 21 oC.  The reaction
mixture was stirred at  21 oC for 10 min and then heated at 60 oC for 1.5 h.  The reaction
mixture was diluted with EtOAc (6 mL) and the resulting solution was washed with
brine (6 mL) and then NH4OH (6 mL).  The combined aqueous layers were extracted
with EtOAc (2 x 6 mL).  The combined organic layers were washed with water (2 x 6
mL) and then washed with brine (2 x 6 mL), dried (Na2SO4), concentrated in vacuo and
purified by flash chromatography (6:1 to 4:1 hexane : EtOAc) to afford 32 mg of 2.27
(56 %) of an orange oil: IR (CH2Cl2) 2922, 1639, 1445 cm-1; 1H NMR (500 MHz,
CDCl3) δ 6.77 (d, J = 8.5 Hz, 1H), 6.70 (d, J = 8.5 Hz, 1H), 5.95 (d, I = 1.5 Hz, 1H),
5.93 (d, J = 1.5 Hz, 1H), 5.01 (d, J = 1.5 Hz, 2H), 3.36 (s, 3H); 13C NMR (126 MHz,
CDCl3) δ 150.8, 146.8, 142.8, 108.6, 107.9, 107.0, 101.6, 96.6, 56.1; HRMS (ESI)
369.1161 [(M + Li)+, calcd for C18H18O8 369.1162].
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Aryl-stannane 2.28.  To a solution of 2.14 (1.03 g, 5.21 mmol) and TMEDA
(0.87 mL, 5.7 mmol) in THF (13 mL) at 0 oC was added n-BuLi ( 3.7 mL of a 1.6 M
solution in hexanes, 5.7 mmol) dropwise.  The ice bath was removed and the reaction
mixture was stirred at 21 oC for 1 h and then cooled to 0 oC.  Trimethyltin chloride (5.7
mL of a 1 M solution in THF, 5.7 mmol) was added and the reaction mixture was
allowed to warm to 21 oC over 1.5 h.  The resulting solution was poured into saturated
NaHCO3 (15 mL) and the product was extracted with EtOAc (3 x 15 mL), dried
(MgSO4), concentrated in vacuo and the resulting residue was purified by flash
chromatography (10:1 hexane : EtOAc) to afford 1.3 g 2.28 (68 %) as a yellow oil: IR
(CH2Cl2) 2918, 1577, 1467 cm-1;1H NMR (500 MHz, CDCl3) δ 6.84 (d, J = 9 Hz, 1H),
6.80 (d, J = 8.5 Hz, 1H), 5.10 (s, 2H), 3.83 (s, 3H), 3.82 (s, 3H), 3.47 (s, 3H), 0.35 (s,
9H); 13C NMR (126 MHz, CDCl3) δ 156.1, 154.3, 147.7, 124.7, 114.4, 108.6, 94.8, 61.1,
56.4, 56.1, -6.8; HRMS (ESI) m/z 385.0415 [(M + Na)+, calcd for C13H22O4Sn
385.0438].
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Biaryl 2.29.  A flask containing Pd(PPh3)4 ( 2.09 g, 1.82 mmol), CuCl (9.00 g,
90.9 mmol), and CuCl2 ( 4.88 g, 36.3 mmol) was purged with argon (3x) and 2.28 ( 6.58
g, 18.2 mmol) in DMSO (182 mL) was added dropwise at 21 oC and the reaction
mixture stirred at 21 oC for 3 d. The mixture was diluted with EtOAc (200 mL) and
resulting solution was washed with brine (2 x 180 mL) and then washed with NH4OH
(180 mL).  The combined aqueous layers were extracted with EtOAc (2 x 180 mL).  The
combined organic layers were washed with water (2 x 180 mL) and then washed with
brine (2 x 180 mL), dried (MgSO4), concentrated in vacuo and the resulting residue was
purified by flash chromatography (6:1 hexane : EtOAc) to afford 1.3 g 2.29 (38 %) as a
light yellow solid: mp 27-29 oC (CH2Cl2); IR (CH2Cl2) 2944, 1595, 1480 cm-1; 1H NMR
(500 MHz, CDCl3) δ 6.91 (d, J = 9 Hz, 1H), 6.77 (d, J = 9.5 Hz, 1H), 5.19 (s, 2H), 3.89
(s, 3H), 3.85 (s, 3H), 3.54 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 149.2, 147.9, 146.8,
119.7, 111.9, 110.8, 96.2, 60.9, 56.7, 56.6; LRMS (ESI) m/z 395 [(M + H)+, calcd for
C20H26O8 395].
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CHAPTER III
CONCLUSION
3.1 Summary
Our recent synthetic efforts have focused on the synthesis of hibarimicinone (1.6) and
HMP-Y1 (1.10), which are key intermediates on the biosynthetic pathway leading to the
more complex hibarimicin B (1.2).  Completion of these synthetic targets will  enable us
to correlate our synthetic products with the natural products, thereby confirming
structural assignment.  Our retrosynthetic analysis of hibarimicinone (1.6) and HMP-Y1
(1.10) are illustrated in Schemes 1.2, 1.3, and 1.4.  The synthetic work accomplished
toward these target intermediates was discussed in Chapter Two.
3.2 Future Work Toward the Synthesis of Hibarimicinone (1.6)
Our synthesis of hibarimicinone (1.6) requires the completion of the Hauser annulation
precursors, followed by a Hauser annulation, and a series of subsequent reactions to
afford the ABCD and EFGH ring stystems, which then will be coupled to afford
hibarimicinone (1.6).
3.2a Future Work Toward the ABCD Ring System
The ABCD ring system will be constructed using the chemistry described in
Scheme 1.2, and shown in detail in Scheme 3.1. We anticipate utilizing a Hauser
annulation between the lactone 3.1 and the enone 3.2 to afford the tetracycle 3.3.  The
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tetracycle 3.3 will then undergo a series of functional group interconversions to afford
the ABCD ring system, and provide one of the necessary coupling partners for the
synthesis of hibarimicinone (1.6).
Scheme 3.1. Future Work Toward the Synthesis of ABCD Ring System.
3.2b Future Work Toward the Synthesis of EFGH Ring System
The model study for the EFGH ring system, Section 2.1, provided some valuable
information for the synthesis of the EFGH ring system.  Using a second generation
approach we envision starting from MOM protected sesamol 3.5 and applying DoM
methodology to derive cyanophthalide 3.6, which may then undergo a Hauser annulation
with the enone 3.7 to afford the dihydroquinone 3.8 as seen in Scheme 3.2.  The
dihydroquinone 3.8 will then be methylated and the MOM ether deprotected to afford
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the free phenol 3.9.  The free phenol 3.9 may be oxidized followed by functional group
interconversion to complete the EFGH ring system 3.10.  The EFGH ring system is the
second tetracycle needed for the palladium cross coupling to furnish hibarimicinone
(1.6).
Scheme 3.2. Future Work Toward the Synthesis of EFGH Ring System.
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3.2c Palladium Mediated Cross-Coupling
Once the ABCD and EFGH ring systems are in hand, we envision using a palladium
mediated cross coupling to couple the tetracycles 3.4 and 3.10, as illustrated in Scheme
3.3.  This transformation may be accomplished in one of several ways, including a
Suzuki or Stille cross-coupling reaction, as previously discussed.  Upon completion of
the cross coupling reaction, the synthesis of hibarimicinone (1.6) will be complete.
Scheme 3.3. Future Work Toward the Synthesis of Hibarimicinone (1.6).
3.3 Future Work Toward the Synthesis of HMP-Y1 (1.10)
The most promising approach to the synthesis of HMP-Y1 involves a dimerization of
the tetracycle 3.13, as shown in Scheme 3.4.  This may be accomplished by utilizing an
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oxidative coupling of tetracycle 3.13.  A Hauser-like annulation between the lactone
3.11 and the enone 3.12 should furnish the tetracycle 3.13, which may then be
oxidatively coupled followed by deprotection to afford HMP-Y1 (1.10).
Scheme 3.4. Future Work Toward the Synthesis of HMP-Y1 (1.10).
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